A Multicenter, Open-label, Single-arm, Phase 4 Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil Mesylate Tablets in Chinese Adolescents (Aged From 12 to Less Than 18 Years) With Chronic Graft-versus-host Disease (cGVHD) Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies
Latest Information Update: 01 Jun 2026
At a glance
- Drugs Belumosudil (Primary)
- Indications Graft-versus-host disease
- Focus Pharmacokinetics
- Sponsors Sanofi
Most Recent Events
- 27 May 2026 Status changed from active, no longer recruiting to completed.
- 22 Jun 2025 Planned End Date changed from 4 May 2026 to 13 May 2026.
- 22 Jun 2025 Planned primary completion date changed from 4 May 2026 to 13 May 2026.